NEW YORK (GenomeWeb) – Becton Dickinson announced today that it has received approval from the US Food and Drug Administration for its BD Max Vaginal Panel for the diagnosis of vaginitis and vaginosis in women who exhibit symptoms of vaginal infections. 

The assay runs on the BD Max System, which combines automated real-time PCR extraction, amplification, and detection on a single platform. It is designed to detect the pathogens responsible for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.